Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

Atreya, Chintamani; Glynn, Simone; Busch, Michael; Kleinman, Steve; Snyder, Edward; Rutter, Sara; AuBuchon, James; Flegel, Willy; Reeve, David; Devine, Dana; Cohn, Claudia; Custer, Brian; Goodrich, Raymond; Benjamin, Richard J.; Razatos, Anna; Cancelas, Jose; Wagner, Stephen; Maclean, Michelle; Gelderman, Monique; Cap, Andrew; Ness, Paul

Overall, the use of PR technology is slowly increasing, and data addressing many of the above-listed concerns are being reported, at least in abstract form. [31] [32] [33] [34] [35] [36] However, the lack of an extensive degree of published US data, especially for pediatric and transplant recipients, coupled with the absence of a strong FDA endorsement of the technology and the high cost of this technology, has hampered widespread acceptance of PR PLTs. 30 The possibility of another bloodborne threat to the safety of the national blood supply seems inevitable. How well we mitigate that threat may well depend on how these issues regarding PR blood products are resolved. It is critical that early adopters of PR technology in the United States publish their experience with utilization of PR PLTs for patient care, especially their pediatric experience.